US-based medical equipment maker ZAP Surgical Systems has closed a $78m Series E funding round, led by Chinese healthcare company Qingdao Baheal Medical with participation from other strategic investors.
The new funding will support the company in commercialising its ZAP-X Gyroscopic Radiosurgery platform, a tumour treatment solution.
The company said the ZAP-X system features a unique gyroscopic design that allows radiosurgical beams to target tumours from thousands of angles, enabling precise targeting while prioritising the protection of healthy brain tissue to help preserve patient cognitive function.
Its vault-free and cobalt-free design removes the need for shielded treatment rooms and eliminates the requirement to manage and replace radioactive isotopes for radiation production.
According to ZAP Surgical Systems, stereotactic radiosurgery (SRS), a non-invasive procedure, is widely used to treat various brain tumours, including brain metastases, meningiomas, and intracranial disorders such as trigeminal neuralgia.
SRS offers a minimally invasive alternative to open surgery, typically delivered in 1 to 5 brief sessions.
Compared to open surgery, SRS provides comparable to superior outcomes without incisions or pain, and usually requires little to no recovery time.
ZAP Surgical Systems founder and CEO John Adler said: “We founded ZAP Surgical to address a clear need: enabling more patients to access state-of-the-art radiosurgery without the prohibitive costs and infrastructure requirements that limit so many providers.
“This partnership with Baheal Medical perfectly aligns with our mission, providing ZAP-X with a powerful platform to reach millions of underserved patients globally.”
Baheal Medical chairman and president Fu Gang said: “We are thrilled to partner with ZAP Surgical in expanding access to cutting-edge radiosurgery technology. ZAP-X’s innovative approach aligns with our commitment to delivering advanced healthcare solutions that address pressing clinical needs.
“Together, we are poised to promote how brain tumours and other intracranial diseases are treated, providing more precise alternatives that greatly enhance patients’ quality of life.”
Earlier this year, the company announced that IMS Shin-Matsudo Central General Hospital in Japan, completed its first patient treatment using the ZAP-X Gyroscopic Radiosurgery platform.
